Loading stock data…
$2.50-0.11 (-4.39%)
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
Protara Therapeutics, Inc. in the Healthcare sector is trading at $2.50 with a market capitalization of $214M. Wall Street consensus targets $25.71 (7 analysts), implying a +926.5% move over the next 12 months. The stock is currently near its 52-week low of $2.50, remaining 47.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.32M↓ | -$19.63M↓ | -$19.08M↓ | -$14.76M↑ | -$16.59M |
| Net Income | -$21.67M↓ | -$17.78M↓ | -$17.31M↓ | -$13.26M↑ | -$14.96M |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in ...